Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update

Shujuan Zhao, Xuejiao Hong, Haixia Cai, Mingzhou Liu, Bing Li, Peizhi MaFrontiers in Cardiovascular Medicine 2021 · DOI

Abstract

Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly for those who have acute coronary syndrome (ACS) and/or are undergoing percutaneous coronary intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, a triple antithrombotic therapy (TAT), which consists of combined oral anticoagulant therapy to prevent systemic embolism or stroke along with dual antiplatelet therapy to prevent coronary arterial thrombosis (CAT), is used. However, TAT has been associated with a significantly increased risk of bleeding. With the emergence of non-vitamin K antagonist oral anticoagulants (NOACs), randomized controlled trials have demonstrated a better risk-to-benefit ratio of dual antithrombotic therapy (DAT) in combination of a NOAC and with a P2Y12 inhibitor than vitamin K antagonist-based TAT. The results of these studies have impacted the recommendations of current international guidelines, which favor a DAT with a NOAC and P2Y12 inhibitor (especially clopidogrel) in this clinical setting. Additionally, aspirin can be administered during the periprocedural period, while the treatment duration of TAT should be as short as possible. In this article, we summarize the up-to-date evidence regarding antithrombotic regimens for AF patients with PCI or ACS, with a specific focus on the optimal approach and critical discussions of key scientific data and future developments for antithrombotic management in these patients.

Introduction: The Balancing Act of Antithrombotic Therapy

Managing patients with both atrial fibrillation (AF) and coronary artery disease (CAD) requires a delicate balance between preventing thromboembolic events and minimizing life-threatening bleeding. AF patients typically require oral anticoagulants (OACs) for stroke prevention. However, when these patients undergo percutaneous coronary intervention (PCI) or experience acute coronary syndrome (ACS), they also require dual antiplatelet therapy (DAPT) to prevent stent thrombosis and recurrent myocardial infarction.

Historically, the standard of care was "Triple Antithrombotic Therapy" (TAT)—a combination of an OAC plus two antiplatelets (typically aspirin and clopidogrel). While effective at preventing ischemic events, TAT is associated with a high risk of major bleeding. Recent evidence suggests a "less is more" approach, shifting the paradigm toward Dual Antithrombotic Therapy (DAT), which combines a newer oral anticoagulant (NOAC) with a single P2Y12 inhibitor.

Evidence from Landmark Clinical Trials

The transition from TAT to DAT is supported by four major Phase 3b/4 randomized controlled trials (RCTs) that have collectively redefined clinical practice. These trials evaluated different NOACs against traditional Vitamin K Antagonist (VKA)-based triple therapy.

Overview of the four landmark randomized controlled trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST-AF PCI) comparing various antithrombotic regimens.

Key Trial Data:

  • PIONEER AF-PCI (Rivaroxaban): Demonstrated that rivaroxaban-based regimens significantly reduced clinically significant bleeding (16.8%–18.0%) compared to VKA-based TAT (26.7%).
  • RE-DUAL PCI (Dabigatran): Showed that dabigatran-based DAT was non-inferior to VKA-based TAT regarding thromboembolic events while significantly reducing bleeding risk.
  • AUGUSTUS (Apixaban): The largest trial (n=4,614) used a 2x2 factorial design. It found that apixaban led to lower rates of major or clinically relevant non-major (CRNM) bleeding (10.5%) compared to VKA (14.7%), and that omitting aspirin further reduced bleeding without a significant increase in ischemic events.
  • ENTRUST-AF PCI (Edoxaban): Confirmed the safety of edoxaban-based DAT, showing it was non-inferior to VKA-based TAT for major or CRNM bleeding.

Global Perspectives and Clinical Guidelines

While international guidelines have moved toward recommending NOAC-based DAT as the default strategy, there are subtle regional differences, particularly regarding the duration of periprocedural aspirin use.

Comparison of antithrombotic strategies and aspirin duration across European, North American, and Chinese clinical perspectives.
  • European Perspective: Recommends stopping aspirin within one week post-PCI for most patients.
  • North American Perspective: Suggests a slightly longer window of 4–6 weeks for patients at high ischemic risk.
  • Chinese Perspective: Generally recommends stopping aspirin at the time of hospital discharge.

Across all regions, clopidogrel remains the preferred P2Y12 inhibitor for combination therapy due to its more favorable safety profile compared to more potent agents like ticagrelor or prasugrel.

Conclusion and Future Directions

The evidence consistently favors NOAC-based Dual Antithrombotic Therapy over traditional VKA-based Triple Therapy for the majority of AF patients undergoing PCI or presenting with ACS. This approach significantly reduces bleeding risk without compromising protection against stroke or stent thrombosis.

However, challenges remain. Most trials were not powered to detect differences in rare ischemic events like stent thrombosis. Future research must focus on personalizing therapy, utilizing predictive models to identify patients who might still benefit from short-term triple therapy versus those who should transition immediately to dual therapy. Additionally, the role of more potent P2Y12 inhibitors in these regimens requires further investigation to optimize the risk-benefit ratio for high-risk individuals.

Summary updated

Abstract

Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly for those who have acute coronary syndrome (ACS) and/or are undergoing percutaneous coronary intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, a triple antithrombotic therapy (TAT), which consists of combined oral anticoagulant therapy to prevent systemic embolism or stroke along with dual antiplatelet therapy to prevent coronary arterial thrombosis (CAT), is used. However, TAT has been associated with a significantly increased risk of bleeding. With the emergence of non-vitamin K antagonist oral anticoagulants (NOACs), randomized controlled trials have demonstrated a better risk-to-benefit ratio of dual antithrombotic therapy (DAT) in combination of a NOAC and with a P2Y12 inhibitor than vitamin K antagonist-based TAT. The results of these studies have impacted the recommendations of current international guidelines, which favor a DAT with a NOAC and P2Y12 inhibitor (especially clopidogrel) in this clinical setting. Additionally, aspirin can be administered during the periprocedural period, while the treatment duration of TAT should be as short as possible. In this article, we summarize the up-to-date evidence regarding antithrombotic regimens for AF patients with PCI or ACS, with a specific focus on the optimal approach and critical discussions of key scientific data and future developments for antithrombotic management in these patients.
BibTeX
@inproceedings{zhao2021antithrombotic,
  author = {Shujuan Zhao and Xuejiao Hong and Haixia Cai and Mingzhou Liu and Bing Li and Peizhi Ma},
  title = {{Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.660986},
}

Loading related content...

Figure